Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.08.15.745036

Physics-Informed Modeling of Biological Aging through DNA Methylation Entropy

Abstract

Epigenetic clocks based on DNA methylation patterns are among the most accurate molecular correlates of chronological age, yet widely used clocks are predominantly empirical models with limited explicit characterization of the underlying methylation variability, lacking a direct connection to the physical mechanisms of aging. In this work, we bridge this gap by introducing an information-theoretic framework for DNA methylation dynamics combined with nonlinear machine learning to develop a competitive and interpretable age predictor. We model the population distribution of methylation {beta}-values at each CpG site using a reparameterized three-parameter Generalized Gamma Distribution (GGD) and derive a closed-form expression for its differential Shannon entropy. The resulting CpG-level entropy is used to characterize methylation variability and as a criterion for locus filtering. We introduce the Stacy Gradient Boosting Clock (Stacy-GB), which combines this GGD-based representation with a LightGBM regressor. The model was evaluated across independent cohorts using the ComputAgeBench epigenetic clock benchmark. Stacy-GB achieved a mean absolute error (MAE) of 3.74 years and a median error (bias) of 2.41 years, significantly outperforming state-of-the-art epigenetic clock baselines. Furthermore, age acceleration estimated by Stacy-GB was associated with several clinical pathologies, including ischemic heart disease, HIV infection, multiple sclerosis, and Werner syndrome, supporting its potential as an accurate and biophysically grounded tool for clinical aging research.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nasrolahpour, H., Jandera, A., Skovranek, T., Despotovic, V., Pellegrini, M.. 2026-08-20. Physics-Informed Modeling of Biological Aging through DNA Methylation Entropy. https://doi.org/10.64898/2026.08.15.745036

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗